



Dabigatran bei Patienten mit Vorhofflimmern:  
Management bei invasiven Eingriffen 
Zusammenfassung  Chirurgische und andere  interven-
tionelle  Eingriffe  erfordern  ein  individuelles  Abwägen 
des  Blutungsrisikos  gegenüber  dem  Thromboserisiko 
des Patienten. Da sich die neuen Antikoagulantien von 
den klassischen Vitamin K Antagonisten und Bezug auf 
Halbwertzeit  und  Laborkontrollen  deutlich  unterschei-
den, sind für diese Substanzen andere Vorgehensweisen 
zu  definieren.  Ziel  der  vorliegenden  Expertenempfeh-
lung ist es, ein optimales perioperatives/interventionel-
les Management  für Patienten zu beschreiben, die eine 
Dauertherapie  mit  dem  kürzlich  zugelassenen  oralen 
Thrombininhibitor  Dabigatran  erhalten.  Anhand  ver-
schiedener klinischer Routinesituationen wird das Vor-
gehen  erläutert  und  der  Evidenzgrad  der  Empfehlung 
angegeben.  Da  ein  Routine-Labortest  zur  Bestimmung 
des Wirkspiegels nicht überall verfügbar ist,  ist auf eine 
sorgfältige Anamnese, einen ausreichenden Zeitabstand 
zwischen  der  letzten  präoperativen  Gabe  von  Dabiga-
tran und dem geplanten Eingriff sowie einer sorgfältigen 
Blutstillung zu achten.
Schlüsselwörter:  Dabigatran,  Bridging,  Chirurgie,  En-
doskopie, Blutung
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Summary  In  any  type  of  invasive  surgery,  the  patient’s 
individual  risk  of  thromboembolism  has  to  be  weighed 
against  the  risk  of  bleeding.  Based  on  various  everyday 
situations  in  clinical  routine,  the  purpose  of  the  present 
expert  recommendations  is  to  provide  appropriate  peri-
operative and periinterventional management for patients 
with  atrial  fibrillation  undergoing  long-term  treatment 
with  the  thrombin  inhibitor  dabigatran.  As  we  currently 
have  no  routine  laboratory  test  to  measure  therapeutic 
levels  of  the  substance  or  the  risk  of  bleeding,  general 
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Background
In any  type of  invasive  surgery,  the patient’s  individual 
risk of thrombosis has to be weighed against the risk of 
bleeding  (and  its  potential  sequelae). This  is  especially 
true  for  patients  who  receive  anticoagulation  therapy. 
This issue has been the subject of numerous clinical stu-
dies, which  formed  the basis  for  the  recommendations 






surgical  or  invasive  procedures,  and  following  acute 
injury  [1].  Systematic  investigations  demonstrating  the 
association  between  dosage,  the  interval  between  the 
last preoperative dose and clinical progress (risk of blee-




are  only  available  for  those  patients  who  underwent 
electrical  cardioversion  during  the  observation  period. 
The European as well as the U.S. American Summary of 
Product Characteristics contain basic information about 
bridging, but specific  recommendations  for  the various 
surgical and interventional procedures are not provided.




and  periinterventional  management  for  patients  with 
atrial  fibrillation  undergoing  long-term  treatment  with 
dabigatran.  As  we  currently  have  no  routine  laboratory 
test to measure therapeutic levels of the substance or the 
risk of bleeding, general measures such as a standardized 








wing. The  recommendations  concerning  bridging  with 
dabigatran, especially the reinstitution of anticoagulation 





The existing  recommendations  of  the  consensus  group 
were formulated on the basis of the following sources of 
data:
1.   Recommendation  for  the  management  of  acute  or 
elective interventions in accordance with the protocol 
of the RE-LY® study.









sus,  i.e., more  than  95 %  of  the  participants  expressed 
their approval. While every care has been taken, the con-
sensus group can take no responsibility for the accuracy 




Table 1. The strength of the expert recommendation is ba-
sed on the classification used to formulate the guidelines of 
the European Society of Cardiology [1]
Class of recommendation
Class 1 Evidence and/or general agreement that a specific medication or 
intervention is beneficial, useful, and effective
Class 2 Nonconcurrent evidence and/or no concurrence that a specific 
medication or intervention is beneficial, useful, and effective
Class 3 Evidence and/or general agreement that a specific medication or 
intervention is not beneficial, useful, or effective. Therefore, the 
medication/measure is not recommended
Level of evidence
Level A Study results from several randomized clinical studies or meta-
analyses
Level B Study results of a randomized clinical study or large nonrando-
mized studies
Level C Consensus opinion of the expert group and/or small studies, 




Pharmacokinetics and effects on coagulation 
assays
Dabigatran  etexilate may  be  taken  independent  of  the 
ingestion  of  food  [3–5]. The  capsule  should  be  swallo-
wed whole. Opening  the  capsule  and  administering  its 
contents  (e.g.,  when  the  substance  is  administered  via 




dosing,  the maximum concentration  in plasma  (Cmax) 
at  steady  state  is  about  30 % higher  than  after  the  first 
dose  [5]. The  half-life  of  dabigatran  is  longer  than  that 














(see  below).  Potential  changes  in  routine  coagulation 
parameters due to dabigatran are summarized in Table 2 
[8,  9]. However,  normal  findings  on  coagulation moni-
toring do not rule out a significant effect of dabigatran. 
In case attempts are made to perform routine diagnostic 
procedures  for  determination  of  the  patient’s  coagula-
tion  preoperatively,  these  should  be  performed  during 
trough  levels,  i.e., prior  to  the next  scheduled  intake of 
dabigatran (Recommendation 1C) [9]. If dabigatran has 
to  be  paused during  the  intervention,  the  preoperative 
diagnostic procedure for coagulation monitoring should 
be performed shortly before  the operation and after an 





In  the  majority  of  patients  the  150  mg  BID  dose  as 
well as  the 110 mg BID dose prolong the activated par-
tial thromboplastin time (aPTT) [8]. During the intake of 
twice daily dose of 150 mg dabigatran, the median peak 













Usually the International Normalized Ratio (INR) and 
Prothrombin Time (PT) are hardly influenced by dabiga-
tran (INR may be normal or slightly increased) [8]. Caution 






The  thrombin  time  (TT)  is  too  sensitive  for monito-
ring dabigatran [5, 8, 9]. However, the TT is most useful 
as a sensitive method for determining if any dabigatran 






the  optimal  therapeutic  range  is  currently  not  known. 
Normalization  of  the  Hemoclot  test  after  discontinua-
tion of dabigatran (e.g., preoperatively) practically rules 
out a significant anticoagulatory effect. In addition to the 
Hemoclot test, Ecarin Clotting Time (ECT) is a sensitive 
test  to  determine  the  anticoagulatory  effect  of  dabiga-
tran, but is performed at just a few centers [8].
The  Activated Clotting Time (ACT)  is  the  most  fre-
quently  used  bedside  coagulation  test  to  measure  the 
anticoagulatory effect of unfractionated heparin during 
cardiac  catheterization  or  any  type  of  cardiac  surgery. 
Dabigatran  causes  a  significant  prolongation of ACT  in 





Tooth extractions or other minor surgical 
procedures
The  Summary  of  Product  Characteristics  provides  no 
recommendations concerning the management of tooth 
Table 2. A summary of the systematic evaluation reveals 
the following potential changes in routine coagulation para-
meters due to dabigatran. (Adapted from [7])
Parameter (unit) Change (dose dependent)
Prothrombin time (PT) (s) ↑
International normalized ratio (INR) ↑
Partial thromboplastin time (aPTT) (s) ↑↑
Thrombin time (TT) (s) ↑↑↑ (to nondetectability)
Activated clotting time (ACT) (s) ↑↑
Fibrinogen assay (Clauss’ method) (mg/dl) ↓↓
Coagulation factors VIII, IX, XI, XII (%) ↓↓
Coagulation factors II, V, VII, X (%) ↓
consensus report
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extractions  or minor  surgical  procedures which  permit 
good  control  of  local  hemostasis.  International  guide-
lines such as  the ACCP guidelines  recommend that  the 
intervention be performed under continuous anticoagu-
lation in the therapeutic target range (INR 2.0–3.0) during 
the  intake  of  VKA,  as  some  studies  have demonstrated 
a higher  risk of  thromboembolism when  the  therapy  is 
discontinued and, conversely, the risk of severe bleeding 
is very low under ongoing anticoagulation [8].
From  orthopedic  studies  with  dabigatran  in may  be 
concluded that the 110 mg dose initiated shortly postsur-
gery (1 to 4 h postoperatively) is safe [10, 11]. The degree 
of  the  risk of bleeding under  the 150 mg BID dose and 
the safety of continuing the preoperative therapy during 
minor surgery are not known.
Based  on  extrapolation  of  the  data  concerning  con-
ventional  anticoagulants  (VKA,  heparin)  and  the  low 









similar  low  rates  of  complications  as  those  in  patients 




110  and  150 mg  dabigatran  BID,  respectively,  as  com-












1.   A  laboratory  testing  of  dabigatran  prior  to  electrical 




The  international  recommendations  for  prevention  of 
systemic  embolism  (cardioversion  for  atrial  fibrillation 
< 48 h or after exclusion of a thrombus by transesopha-
geal  echocardiography,  otherwise  no  earlier  than  after 
3 weeks of therapeutic anticoagulation) must, of course, 
be followed.
Catheter ablation for atrial fibrillation (isolation  
of the pulmonary vein)
As we have data confirming the safety of ablation of atrial 
fibrillation  under VKA  (INR  2.0–3.0)  [14],  the  following 
procedure  may  be  concluded  by  analogy  and  recom-

























for  catheter-based  interventions.  Due  to  the  potential 
risk of complications and  the possible need  for cardiac 




























val  the  patient may  be  given  oral  anticoagulation with 
VKA aimed at a target INR of 2.0–2.5 [15].
Endoscopic low-risk interventions  
in the gastrointestinal tract and low-risk  
vessel punctures
Endoscopic  low-risk  interventions  include  gastroscopy 
or colonoscopy with or without diagnostic biopsies of the 
mucosa,  biliary  stent  implantation  and  endosonogra-
phy (without biopsy). Low-risk vessel punctures include 




dations  are  provided  in  the  Summary  of  Product  Cha-
racteristics  for  the management of patients undergoing 
treatment with dabigatran.
The international recommendations  for  the  intake of 
VKA  suggest  that  these  low-risk  interventions  may  be 
performed under ongoing anticoagulation in the thera-
peutic  target  range  (INR 2.0–3.0) because  some studies 
have  demonstrated  a  high  risk  of  thromboembolism 
when the therapy is discontinued, and the risk of severe 
bleeding is very low [16, 17]. The same recommendation 











Endoscopic high-risk interventions,  


















interventions  in  patients  undergoing  treatment  with 
dabigatran. The  international  recommendations  for  the 









of  renal  failure  (creatinine  clearance  < 50  ml/min; 
Recommendation 1C).
3.   Treatment  with  dabigatran  should  be  continued  on 
the  evening  of  the  intervention,  but  no  earlier  than 
4 h after the intervention (Recommendation 1C). In 
cases of a higher risk of bleeding due to the interven-
tion  and  lower  risk  of  thrombosis  in  the  individual 
patient, one may consider delayed reinstitution of the 
therapy  (24–72  h  postinterventional; Recommenda-
tion 1C).
Major surgery
Major  surgical  procedures  are  defined  as  those  asso-




Table 3. Operations or interventions with a high risk of 
bleeding or a high risk of severe complications in the event 
of bleeding. (Adapted from ACCP guidelines; [8])
Aortocoronary bypass operation
Cardiac valve surgery
Surgery for aneurysm of the aorta
Neurosurgical interventions or neuraxial anesthesia




Urological operations in the prostate gland or bladder
Revision surgery for bleeding or infection
consensus report
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management  of  patients  with  atrial  fibrillation  recom-
mend interruption of oral anticoagulation during major 
surgery  [9].  If  the  therapy  is paused  for a  longer period 
of time and the risk of thromboembolism is high, LMWH 
therapy  is  recommended  preoperatively.  Postoperati-
vely, depending on the type of surgery and the patient’s 





bleeding)  of  dabigatran have  been  established  only  for 
these interventions. As the risk of bleeding is rather high 
during  the  first  few days  postsurgery,  therapeutic  anti-
coagulation  should  be  reinstituted  only  after  adequate 
hemostasis has been achieved (usually after 48–72 h).
The  Summary  of  Product  Characteristics  provi-
des  recommendations  for  the management  of  surgical 
interventions  in  patients  with  atrial  fibrillation  under-
going  treatment  with  dabigatran  [5].  These  recom-








should  be  discontinued  2  days  in  case  of  creatinine 
clearance  50–80 ml/min  or  interventions  associated 




patients with  atrial  fibrillation  and  a  CHADS2  score 
> 2  or  those  who  have  experienced  an  acute  ische-
mic  cerebrovascular  syndrome  the  clinician  should 




mendation  1C).  According  to  the  international  re-
commendations, therapeutic doses of LMWH should 
be concluded at the latest 24 h before the intervention.
4.   Postoperative  prophylaxis  of  venous  thrombosis 
should be administered  in accordance with  interna-
tional  recommendations  (early  mobilization,  drug-
based prophylaxis; Recommendation 1A)
5.   Treatment with dabigatran at  the usual dose  (150 or 
110 mg BID) should be continued from the third post-





of  bleeding  or  high-risk  patients,  the  clinician  may 
consider  delayed  reinstitution  of  dabigatran  therapy 
(Recommendation 1C).
Remark  on  4: Dabigatran  is  only  approved  for  prophy-











the management of  these  interventions on  the basis  of 
the instructions of the RE-LY study protocol [5]. In addi-
tion  to  general measures  for  hemostasis  such  as  com-
pression,  volume  substitution,  banked  blood,  etc.,  the 
following recommendation may be issued [20]:
1.   Before an acute  intervention, a diagnostic  investiga-
tion of coagulation for the purpose of orientation—or 
if  available  a  dabigatran-sensitive  laboratory  test—
may  help  to  estimate  the magnitude  of  the  existing 
anticoagulation  in order  to perform additional mea-
sures or postpone  the  intervention  if necessary  (Re-
commendation  1C).  A  normal  thrombin  time  (TT) 
might rule out a significant effect of dabigatran but TT 
is  often  prolonged  in  clinical  routine  and  especially 













of  the  active  substance  can be hemodialyzed within 
2–3 h; Recommendation 1C).
4.   In  case  of  life-threatening  bleeding,  the  following 
medications may be used:  fresh-frozen plasma, pro-
thrombin  complex  concentrate,  FEIBA,  or  recombi-
nant factor VIIa (Recommendation 1C).
5.   Platelet concentrates should be given in case of simul-













The  consensus  group  convened  by  the  coordinator 
(A. Weltermann) was multidisciplinary and was consti-
tuted in a representative manner for the circle of addres-
sees  (general  practitioners,  surgeons,  anesthetists,  and 
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